SCHEMBL3017443

SCHEMBL3017443

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(F)c4)CC3)n2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
RORC P51449 1/20 0.40
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
GPR6 P46095 3/20 0.38
KCNQ1 P51787 1/20 0.38
HTR2A P28223 3/20 0.37
HTR2C P28335 3/20 0.37
KCNH2 Q12809 3/20 0.37
DRD2 P14416 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
AR P10275 1/20 0.37
HTR6 P50406 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012854 0.93 THRB (0.41) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3008557 0.91 MAPT (0.46) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3004393 0.91 MEN1 (0.41) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3018532 0.90 MAPT (0.36) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3004005 0.90 F2 (0.40) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3022153 0.90 MAPT (0.43) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3017614 0.88 MAPT (0.41) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3018482 0.88 SMN1; SMN2 (0.43) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3020230 0.88 KDM4E (0.42) MAPTUSP2RECQLHSD17B10LMNA
SCHEMBL3014427 0.87 MAPT (0.45) MAPTUSP2RECQLHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.